Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Invested Capital (2016 - 2025)

Vistagen Therapeutics' Invested Capital history spans 12 years, with the latest figure at $50.9 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 37.23% year-over-year to $50.9 million; the TTM value through Dec 2025 reached $50.9 million, down 37.23%, while the annual FY2025 figure was $70.4 million, 38.41% down from the prior year.
  • Invested Capital for Q4 2025 was $50.9 million at Vistagen Therapeutics, down from $66.3 million in the prior quarter.
  • Across five years, Invested Capital topped out at $123.3 million in Q4 2023 and bottomed at $6.8 million in Q2 2023.
  • The 4-year median for Invested Capital is $80.7 million (2021), against an average of $76.1 million.
  • The largest annual shift saw Invested Capital soared 1810.19% in 2021 before it crashed 45.84% in 2025.
  • A 4-year view of Invested Capital shows it stood at $80.0 million in 2021, then skyrocketed by 54.15% to $123.3 million in 2023, then tumbled by 34.2% to $81.1 million in 2024, then tumbled by 37.23% to $50.9 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Invested Capital are $50.9 million (Q4 2025), $66.3 million (Q3 2025), and $56.8 million (Q2 2025).